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Abstract Chronic pressure overload induces cardiac tissue 
remodeling. Chymase is known to regulate matrix metabolism 
and angiotensin II formation. In the present study, we 
investigated the pathophysiological functions of chymase in the 
pressure-overloaded hamster heart induced by a two-kidney, one-
clip (2K1C) hypertension procedure. Fibrosis and apoptosis were 
observed in the pressure-overloaded hearts of 2K1C hamsters 32 
weeks after clipping, but these histological changes were not 
detected at 16 weeks. Heart chymase-like activity of 2K1C 
hamsters at 32 weeks increased 5.2-fold compared with that at 16 
weeks, while angiotensin-converting enzyme was not activated. 
Chymase might be involved in cardiac tissue remodeling during 
the chronic stage of hypertension. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Chymase is a chymotrypsin-like serine protease and is able 
to hydrolyze a variety of substrates including extracellular 
matrix [1-3], metalloproteases [4,5], vasoactive substances 
[6-8], cytokines [9], and lipoproteins [10]. However, its precise 
in vivo pathophysiological role as well as the actual substrate 
for chymase have not been determined. Chymases of human, 
monkey, dog, and hamster are highly efficient in converting 
angiotensin (ANG) I to A N G II [11-17], and the chymase-
dependent A N G II-forming pathway is recognized as a major 
pathway for A N G II formation in cardiovascular tissues. 
A N G II is a potent bioactive peptide with diverse actions, 
and is involved in the paracrine regulation of cardiovascular 
tissue remodeling [18]. Our recent studies demonstrated that 
chymase was upregulated in the process of myointimal hyper-
trophy after balloon catheterization [16]. This result suggests 
that chymase is involved in the mechanisms of vascular tissue 
remodeling through the production of A N G II. Chymase has 
also been identified in the human heart [13], but the possible 
roles of chymase in the pathogenesis of cardiac diseases have 
not been determined. 
Hypertension is a major risk factor of heart failure. Chronic 
pressure overload has been shown to induce dysfunction of 
myocardial contractile tissue with loss of myocytes and ven-
tricular fibrosis after the compensated stage of hypertrophy 
[19,20]. Myocyte loss and fibrosis are also recognized in the 
human heart in patients with chronic hypertension [21]. Many 
studies have been performed to investigate the factors pro-
moting myocyte growth and the synthesis of extracellular ma-
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trix. However, the precise mechanisms for the transition from 
compensated hypertrophy to heart failure have not been es-
tablished. In the process of tissue remodeling, growth factors 
and tissue proteases regulate the formation of extracellular 
matrix and cellular components. In the present study, we in-
vestigated the pathophysiological functions of chymase in 
hamster heart during the chronic stage of hypertension. 
2. Materials and methods 
2.1. Animal treatments 
Six-week-old male Syrian hamsters weighing 90-110 g were pur-
chased from SLC Japan (Shizuoka, Japan) and divided into two 
groups: the two-kidney, one-clip (2K1C) renal hypertensive group 
and the sham-operated control group. The 2K1C hypertension was 
induced as reported previously [22]. Sixteen weeks and 32 weeks after 
the procedure, blood pressure was measured, and the animals were 
killed by decapitation under pentobarbital anesthesia and the hearts 
were collected. The experimental procedures for animals were in ac-
cordance with our institutional guidelines. 
2.2. Measurement of angiotensin-converting enzyme (ACE) and 
chymase-like activities 
Heart ACE activity was determined using the synthetic substrate 
hippuryl-histidyl-leucine (HHL, Peptide Institute, Inc., Minoh, Japan) 
specifically designed for ACE [22]. Heart chymase-like activity was 
measured using the procedure of Okunishi et al. with modifications 
[12,17]. 
2.3. In situ detection of DNA fragmentation 
Apoptotic cells were identified using the terminal deoxynucleotidyl 
transferase UTP nick end labeling assay [23]. Hearts were collected 
from the 2K1C and sham-operated control hamsters 16 and 32 weeks 
after operation, and fixed in 10% neutral buffered formalin and em-
bedded in paraffin. Paraffin sections (5 |xm) were mounted on slides, 
and in situ detection of apoptosis was performed with an ApopTag kit 
(Oncor, Gaithersburg, MD, USA). To assess the myocardial fibrosis 
and calcification, paraffin sections from each heart were stained with 
azan and subjected to von Kossa's method for calcium. 
2.4. In vitro detection of DNA fragmentation 
Genomic DNA was extracted from the hearts of 2K1C hamsters 16 
and 32 weeks after clipping and from the sham-operated control 
hamsters 32 weeks after the operation using the TurboGen genomic 
DNA purification kit (Invitrogen, San Diego, CA, USA). Three mi-
crograms of genomic DNA were electrophoretically separated on 2% 
agarose gels and stained with ethidium bromide. 
2.5. Statistical analysis 
All numerical data shown in the text are expressed as mean± 
S.E.M. Significant differences between the means of different groups 
were evaluated by Student's Mest for unpaired data. 
3. Results 
The mean blood pressure of 2K1C hamsters 16 weeks after 
clipping was higher (162 ± 7 mm Hg, n = 5) than that of age-
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Fig. 1. Histological sections of hearts of 2K1C hypertensive hamsters 32 weeks after clipping. A: Atherosclerotic degeneration of an intramural 
arteriole in the left ventricle (hematoxylin-eosin stain, original magnification X200). B: Calcification of an intramural arteriole in the left ven-
tricle (von Kossa's method for calcium, original magnification X200). C: Left ventricle showing extensive myocardial fibrosis (azan stain, origi-
nal magnification X100). D: In situ detection of DNA fragmentation in hamster heart employing an Apoptag kit. Arrowheads indicate positive 
staining of nuclei in cardiomyocytes (original magnification X400). 
matched sham-operated control hamsters (112 ±5 mm Hg, 
n = 5, P<0.01) and remained high 32 weeks after clipping 
(146 ±2 mm Hg, « = 6, versus 107 ±3 mm Hg, n = 6, 
P<0.01). The heart weight of 2K1C hamsters was signifi-
cantly higher than that of age-matched controls, at 16 weeks 
(436 ±12 versus 321 ±11 mg, « = 5, F<0.01) and 32 weeks 
(440 ±18 versus 348 ±7 mg, « = 5, P<0.01). Widespread 
myocardial fibrosis and atherosclerotic degeneration of small 
branches of the coronary artery were observed in the hearts of 
2K1C hypertensive hamsters 32 weeks after clipping (Fig. 1A-
C). The results of in situ DNA end labeling with the terminal 
deoxynucleotidyl transferase assay showed that apoptosis oc-
curred in the cardiomyocytes of 2K1C hypertensive hamsters 
32 weeks after clipping (Fig. ID). These histological abnor-
malities were not detected in the hearts of 2K1C hamsters 16 
weeks after clipping and in sham-operated control hamsters 
16 weeks and 32 weeks after operation. The oligonucleosomal 
laddering in DNA was detected clearly in the genomic DNA 
extracted from 2K1C hamsters 32 weeks after clipping, but 
not in age-matched sham-operated controls and 2K1C ham-
sters 16 weeks after clipping (Fig. 2). The heart chymase-like 
activity of 2K1C hamsters 32 weeks after clipping exhibited a 
5.2-fold increase when compared with that 16 weeks after 
clipping (Fig. 3A), while the heart ACE was not activated 
throughout the experimental period (Fig. 3B). The heart 
ACE and chymase-like activities of the sham-operated con-
trols were not changed between 16 weeks and 32 weeks after 
the sham operation (Fig. 3). 
4. Discussion 
The present study demonstrated for the first time that chy-
mase was markedly activated during the chronic stage (32 
weeks after clipping) of the 2K1C hypertensive heart concur-
rently with the development of cardiac fibrosis. Hamster chy-
mase, like human chymase, is a highly efficient ANG II-form-
ing enzyme [17]. ANG II is known to promote fibroblast 
proliferation and collagen synthesis in order to induce myo-
cardial fibrosis [18]. Recently, we also demonstrated that the 
cardiac chymase-like activity in BiO 14.6 cardiomyopathic 
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Fig. 2. Nucleosome-sized fragmentation of genomic DNA extracted 
from hearts. Lane 1, DNA marker; lane 2, 2K1C hamster 16 weeks 
after clipping; lane 3, 2K1C hamster 32 weeks after clipping; lane 
4, sham-operated control hamster 32 weeks after operation. 
hamsters increased significantly with the development of car-
diac fibrosis, while ACE was not upregulated in the cardio-
myopathic heart throughout the experimental period [24]. 
After chronic therapy with the ANG II receptor antagonist, 
the area of cardiac fibrosis in BiO 14.6 cardiomyopathic ham-
sters was markedly reduced by 53% [24]. These results sug-
gested that augmented ANG II formation through a chymase-
dependent pathway might be involved in cardiac tissue remod-
eling. However, recent clinical observations demonstrated that 
chymase expression is not upregulated in the terminal-stage 
failing heart [25]. In the present study, hypertensive hamsters 
did not yet show any clinical symptoms of heart failure such 
as increase of body weight and liver mass, or the appearance 
of pleural and peritoneal fluids 32 weeks after clipping. Chy-
mase might be activated in the initial step of the transition 
state from compensated hypertrophy to heart failure, where 
the process of tissue remodeling including myocyte loss and 
fibrosis are most activated. 
Chymase is also known to be involved in the regulation of 
the proteolysis of extracellular matrix [1-3]. Extracellular ma-
trix has the ability to bind growth factors such as basic fibro-
blast growth factor, TGF-J31, and GM-CSF. Human chymase 
was shown to activate procollagenase directly [5], and to lib-
erate latent TGF-[31 from the extracellular matrix [26]. In 
addition, chymase was shown to digest fibronectin and vitro-
nectin, and alter cellular functions by preventing cell-matrix 
interaction [2,3]. Over-expressed heart chymase was predicted 
to exaggerate the destruction of the cardiac interstitium, and 
the excessive amount of growth factors would be liberated 
from the matrix. These growth factors, cooperating with 
ANG II, could then promote the excessive wound-healing 
response resulting in cardiac fibrosis. Chymase may have a 
prevalent role in the complex network formed between ma-
trix-producing factors and proteinases. 
Recent observations indicated the possibility that apoptosis 
might account for the cardiomyocyte loss in the process of 
heart remodeling [20,27-29]. It was suggested that hypoxia 
induces apoptosis in cultured cardiomyocytes [30]. In the 
present study, the small ventricular arteries of 2K1C hamsters 
showed atherosclerotic degeneration at 32 weeks. This histo-
logical change might induce a reduction in coronary blood 
flow and the hypoxic condition of the myocardium. Chymase 
was shown to stimulate cholesterol accumulation in macro-
phages and in vascular smooth muscle cells, and to be in-
volved in the pathogenesis of atherosclerosis [10]. Our pre-
vious report demonstrated that chymase was activated in 
hypertrophied vessels in response to balloon catheterization, 
and promoted the mechanisms of vascular remodeling 
through the production of ANG II [16]. Furthermore, ANG 
II induced oncogenes such as c-fos and c-myc in myocytes 
[31]. These factors have also been reported to regulate the 
process of apoptosis [32,33]. Chymase might be involved in 
the apoptosis of cardiomyocytes through the production of 
ANG II or the modulation of cell-matrix interaction. 
In conclusion, the present study demonstrated for the first 
Fig. 3. Heart chymase-like activity (A) and ACE activity (B) of 2K1C hypertensive hamsters and sham-operated control hamsters 16 weeks 
and 32 weeks after operation. The number of hamsters is shown in parentheses. The vertical bars represent S.E.M. *P<0.05. NS, not signifi-
cant. 
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time that heart chymase was activated in the chronic pressure-
overloaded heart, and might be involved in heart remodeling 
in the transition state to heart failure. A full understanding of 
the pathogenetic role of heart chymase requires further experi-
ments using specific inhibitors for chymase. 
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